Partnerships Archives

News and Trends 23 Dec 2022

InSitu Biologics and Mayo Clinic to co-develop anti-cancer therapeutics

InSitu Biologics, Inc. has entered into an agreement with the Mayo Foundation for Medical Education and Research to further develop its prolonged-release drug delivery technology for anti-cancer therapeutics. The company has developed an industry-leading platform technology for loading large doses of a variety of medications into a localized delivery matrix. Once injected, medication elutes from […]

December 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Dec 2022

Japanese companies look to reduce environmental impact

Japanese companies Astellas Pharma Inc., Eisai Co., Ltd., Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical Company Limited have agreed a collaboration to reduce the environmental impact of pharmaceutical packaging. Based on the agreement, the four companies will aim to promote the use of more environmentally-friendly packaging for pharmaceutical products by sharing knowledge on packaging technologies […]

December 22, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Ethris and DIOSynVax to develop mRNA betacoronavirus vaccine

Ethris GmbH is to collaborate with U.K.-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of betacoronaviruses. The efforts will utilize Ethris’ mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilization platforms. The collaboration is founded on a $42 million award to DIOSynVax by the […]

December 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Pfizer diabetes and obesity study triggers Sosei Heptares windfall

Sosei Group Corporation has been notified by Pfizer that the first subject in a phase 2 clinical trial has been dosed with Pfizer’s candidate PF-07081532. This triggers a $10 million payment to Sosei Heptares. PF-07081532 is a once-daily, next-generation oral small molecule GLP-1 receptor agonist in development for the treatment of type 2 diabetes and obesity. […]

December 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Dec 2022

Ori Biotech and Inceptor Bio partner on solid tumor cell therapy

Cell and gene therapy (CGT) company Ori Biotech, and cell therapy firm Inceptor Bio have announced a new partnership. The deal will utilize Ori Biotech’s manufacturing platform technology to support initial process development through scale-up for manufacturing of Inceptor’s novel CAR-M, CAR-T and CAR-NK programs. Inceptor Bio is the third partner to join Ori’s LightSpeed […]

December 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 20 Dec 2022

Ribbon Biolabs milestone to lead to 2023 market entry

DNA synthesis company Ribbon Biolabs has announced the successful implementation of its InfiniSynth platform for the automated assembly of sequence-agnostic and long DNA. The company achieved the milestone in collaboration with HighRes Biosolutions, a laboratory automation technology company. The InfiniSynth platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach […]

December 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

Ordaōs and Yatiri Bio to tackle AML

Ordaōs has announced a joint development agreement to create new therapeutics for two novel targets in acute myeloid leukemia (AML) with Yatiri Bio. Ordaōs is a biotechnology company designing novel mini-proteins to help drug hunters deliver life-saving treatments, and Yatiri Bio is a biotechnology company that has developed a proprietary platform that links patient proteomic […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

Sanofi and Innate Pharma expand natural killer cell deal

Sanofi and Innate Pharma SA have expanded their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKET (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKET targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

Nykode Therapeutics and Richter-Helm BioLogics announce partnership

Nykode Therapeutics ASA has entered into a strategic manufacturing partnership with Richter-Helm BioLogics GmbH & Co KG to supply plasmid DNA for Nykode’s wholly owned and partnered product portfolio. “We are excited about the strategic manufacturing partnership with Richter-Helm BioLogics. As a leading manufacturer of DNA vaccines, they will provide the long-term expertise and capacity […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Dec 2022

Swedish research center expanding to take on antimicrobial resistance

Research on antibiotic resistance will get a boost when the Center for Antibiotic Resistance Research (CARe) in Gothenburg, Sweden, expands. Bacterial resistance to antibiotics is one of the most serious global health threats. More than a million people die annually as a direct result of infections caused by resistant bacteria. Lack of effective antibiotics jeopardizes […]

December 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Dec 2022

Sosei Heptares and Lilly enter agreement on diabetes and metabolic diseases

Sosei Group Corporation has entered a drug discovery collaboration with Eli Lilly and Company to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with diabetes and metabolic diseases. The agreement will leverage Sosei Heptares’ StaR technology and structure-based drug design (SBDD) platform and Lilly’s drug development and commercialization […]

December 16, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

Cyclica and SK Chemicals to co-develop novel therapeutics

Cyclica Inc. and SK Chemicals Co., Ltd. have announced an AI-driven drug discovery and development partnership to develop therapies across a range of disease areas. Under this collaboration, Cyclica will deploy its proprietary drug discovery platforms to identify novel drug candidates for challenging biological targets across therapeutic areas of mutual interest to both companies. SK […]

December 15, 2022 - 2 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Partnerships

InSitu Biologics and Mayo Clinic to co-develop anti-cancer therapeutics

Japanese companies look to reduce environmental impact

Ethris and DIOSynVax to develop mRNA betacoronavirus vaccine

Pfizer diabetes and obesity study triggers Sosei Heptares windfall

Ori Biotech and Inceptor Bio partner on solid tumor cell therapy

Ribbon Biolabs milestone to lead to 2023 market entry

Ordaōs and Yatiri Bio to tackle AML

Sanofi and Innate Pharma expand natural killer cell deal

Nykode Therapeutics and Richter-Helm BioLogics announce partnership

Swedish research center expanding to take on antimicrobial resistance

Sosei Heptares and Lilly enter agreement on diabetes and metabolic diseases

Cyclica and SK Chemicals to co-develop novel therapeutics

Subscribe to our newsletter to get the latest biotech news!